0000899243-19-016484.txt : 20190611
0000899243-19-016484.hdr.sgml : 20190611
20190611183830
ACCESSION NUMBER: 0000899243-19-016484
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190607
FILED AS OF DATE: 20190611
DATE AS OF CHANGE: 20190611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HALE DAVID F
CENTRAL INDEX KEY: 0001024004
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50549
FILM NUMBER: 19892112
MAIL ADDRESS:
STREET 1: 1042-B NORTH EL CAMINO REAL, SUITE 430
CITY: ENCINITAS
STATE: CA
ZIP: 92024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: GTX INC /DE/
CENTRAL INDEX KEY: 0001260990
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 621715807
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 17 W PONTOTOC AVE.
STREET 2: SUITE 100
CITY: MEMPHIS
STATE: TN
ZIP: 38103
BUSINESS PHONE: 901-523-9700
MAIL ADDRESS:
STREET 1: 17 W PONTOTOC AVE.
STREET 2: SUITE 100
CITY: MEMPHIS
STATE: TN
ZIP: 38103
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-06-07
0
0001260990
GTX INC /DE/
ONCT
0001024004
HALE DAVID F
C/O ONCTERNAL THERAPEUTICS, INC.
12230 EL CAMINO REAL, SUITE 300
SAN DIEGO
CA
92130
1
0
0
0
Common Stock
2019-06-07
4
A
0
699406
A
699406
I
By Hale BioPharma Ventures, LLC.
Common Stock
2019-06-07
4
A
0
18346
A
18346
I
By Hale Trading Company.
Warrants
6.13
2019-06-07
4
A
0
3292
A
2022-09-12
Common Stock
3292
3292
I
By Hale BioPharma Ventures, LLC.
Pursuant to the Agreement and Plan of Merger dated as of April 30, 2019 (the "Merger Agreement"), by and among Oncternal Therapeutics, Inc. ("Old Oncternal"), GTx, Inc. ("GTx") and certain of their subsidiaries, on June 7, 2019 (the "Effective Time"), GTx was merged with and into Old Oncternal, with GTx surviving as the continuing entity. At the Effective Time, each share of Old Oncternal common stock issued and outstanding immediately prior to such time was converted into the right to receive 0.073386 shares of the Issuer's common stock. On the trading day immediately prior to the effective time, the closing price of the Issuer's common stock was $1.20 per share.
The warrants are currently exercisable.
/s/ Hazel M. Aker, Attorney-in-fact
2019-06-11